Track market-moving stories before they get noisy

Wall Street analysts expect Boston Scientific (BSX - Free Report) to post quarterly earnings of $0.76 per share in its upcoming report, which indicates a year-over-year increase of 1.3%. Revenues are expected to be $5.17 billion, up 2.1% from the year-ago quarter.

The consensus EPS estimate for the quarter has been revised 0.5% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.

Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.

While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.

That said, let's delve into the average estimates of some Boston Scientific metrics that Wall Street analysts commonly model and monitor.

Analysts predict that the 'Net Sales- MedSurg- Worldwide' will reach $1.75 billion. The estimate indicates a year-over-year change of +1.6%.

Analysts forecast 'Net Sales- Cardiovascular- Worldwide' to reach $3.32 billion. The estimate points to a change of -0.7% from the year-ago quarter.

The combined assessment of analysts suggests that 'Net Sales- MedSurg- Endoscopy- Worldwide' will likely reach $756.70 million. The estimate indicates a year-over-year change of +1.3%.

The consensus among analysts is that 'Net Sales- MedSurg- Neuromodulation- Worldwide' will reach $308.03 million. The estimate suggests a change of +5.1% year over year.

Analysts expect 'Net Sales- MedSurg- Urology- Worldwide' to come in at $667.93 million. The estimate indicates a change of -2.1% from the prior-year quarter.

The consensus estimate for 'Net Sales- Cardiovascular- Watchman- Worldwide' stands at $449.61 million. The estimate suggests a change of -12.2% year over year.

According to the collective judgment of analysts, 'Net Sales- Cardiovascular- Electrophysiology- Worldwide' should come in at $801.01 million. The estimate indicates a change of -7.4% from the prior-year quarter.

It is projected by analysts that the 'Net Sales- Cardiovascular- Cardiac Rhythm Management (CRM)- Worldwide' will reach $545.12 million. The estimate indicates a change of -5.7% from the prior-year quarter.

The average prediction of analysts places 'Net Sales- Cardiovascular- Interventional Cardiology & Vascular Therapies- Worldwide' at $1.19 billion. The estimate indicates a year-over-year change of +73.5%.

The collective assessment of analysts points to an estimated 'Geographic Revenue- U.S.' of $3.22 billion. The estimate indicates a change of -2.3% from the prior-year quarter.

Analysts' assessment points toward 'Geographic Revenue- Rest of the World' reaching $1.84 billion. The estimate indicates a year-over-year change of +3.8%.

View all Key Company Metrics for Boston Scientific here>>>

Shares of Boston Scientific have experienced a change of +3% in the past month compared to the -1.2% move of the Zacks S&P 500 composite. With a Zacks Rank #4 (Sell), BSX is expected to underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

SummaryBoston Scientific remains a 'hold' as growth decelerates and competitive pressures intensify, particularly in Watchman and electrophysiology segments.Management has shifted the growth focus to Interventional Cardiology, Endoscopy, and Neuromodulation, but meaningful improvements are not expected until 2028.Recent product recalls, a cybersecurity incident, and repeated guidance cuts further cloud near-term visibility and risk further downward revisions.Despite improved margins and a strong innovation pipeline, BSX's risk/reward profile is not compelling enough for a buy at current valuation.Solskin/DigitalVision via Getty Images

Boston Scientific (BSX) is headquartered in Massachusetts and was founded in 1979. As a specialist in medical devices, their business is driven by two key segments: Cardiovascular and MedSurg. The former represented about 2/3rd of their Q2 2026 revenue, in

1.38K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of SYK either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

NEW YORK--(BUSINESS WIRE)---- $BSX #NYSE--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Boston Scientific Corporation (NYSE: BSX) failed to manage Boston Scientific in an acceptable manner, breaching their fiduciary duties to Boston Scientific, and whether Boston Scientific and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know: On February 4, 2026, B.

Key Takeaways Boston Scientific's Q3 2026 revenues are projected to rise 2.1% to $5.17 billion, while EPS may grow 1.3%.BSX's MedSurg may gain from Endoscopy, Neuromodulation and Nalu Medical amid ongoing Urology pressures.BSX's Cardiovascular unit may have benefited from imaging, embolization tech and vascular portfolio growth.
Boston Scientific Corporation (BSX - Free Report) is slated to report third-quarter 2026 results on Oct. 28, before the market opens.

The renowned medical device manufacturer posted earnings per share (EPS) of 86 cents in the last reported quarter, which surpassed the Zacks Consensus Estimate by 3.61%. The company topped earnings estimates in three of the trailing four quarters and broke even once, the average surprise being 2.95%.

BSX’s Q3 EstimatesFor the third quarter of 2026, the Zacks Consensus Estimate for Boston Scientific’s revenues is pegged at $5.17 billion, indicating an increase of 2.1% from the year-ago reported figure.

The Zacks Consensus Estimate for the company’s third-quarter EPS suggests a 1.3% rise to 76 cents. The estimate has dropped 5% in the past 30 days.

Let’s briefly review the company’s performance leading up to this announcement.

What May Have Influenced BSX’s Q3 Performance?MedSurgIn the third quarter of 2026, the segment may have contributed due to continued strength in Endoscopy and Neuromodulation. Endoscopy sales are likely to have gained from the biliary franchise, led by the AXIOS Stent and Delivery System, and the core gastrointestinal (GI) franchise. Boston Scientific also secured FDA clearance for RIVOS, a first-of-its-kind single device designed to consolidate multiple exchanges, allowing physicians to streamline procedural steps while performing endoscopic ultrasound biliary drainage. Initial cases had received positive feedback.

Neuromodulation is likely to have benefited from the strength of its comprehensive pain portfolio, led by the Intracept Intraosseous Nerve Ablation System. The acquired Nalu Medical may have provided another quarter of solid sales contribution, with integration efforts continuing. In the brain franchise, Boston Scientific’s global growth may have been favorably supported by the continued adoption of the Cartesia X leads and accelerating uptake of the Illumina 3D programming algorithm in the United States.

Meanwhile, similar to the previous quarter, Urology may have faced continued headwinds from weakness in the stone franchise due to volume-based procurement in China and commercial disruption in sacral neuromodulation.

The Zacks Consensus Estimate projects MedSurg revenues to increase 1.6% year over year in the third quarter.

CardiovascularIn the third quarter of 2026, Boston Scientific may have faced continued weakness in two historically strong Cardiovascular businesses. During the July earnings call, management lowered its full-year organic revenue and profitability outlook, citing a more challenging second half of 2026 than previously expected. WATCHMAN sales were hurt by an unexpected slowdown in the U.S. market, as compounding clinical evidence impacted referral patterns. In Electrophysiology (“EP”), the level of competitive share movement in the U.S. market was greater than anticipated.

The Cardiac Rhythm Management (“CRM”) business may remain a drag on the quarter’s results, reflecting continued competitive pressures and gaps within the product portfolio.  Weakness across its low-voltage and high-voltage businesses is likely to have persisted. On a positive note, strength across the company’s broad diagnostic portfolio may have helped offset some of the pressures.

Boston Scientific is also expected to have seen sustained momentum in its Interventional Cardiology business, driven by continued strength in DCB, imaging and complex PCI. Vascular Therapies results may benefit from broader adoption of Varithena and the drug-eluting portfolio. Following strong reception of the SEISMIQ IVL device for its clinical differentiation, the company is likely to have continued to ramp up its supply.

Interventional Oncology and Embolization is also expected to have delivered strong global growth, aided by demand for its broad range of technologies.

According to the Zacks Consensus Estimate, Cardiovascular revenues are expected to see a 0.7% decline from the prior-year period.

What Our Model Unveils for BSXPer our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here, as you can see.

Earnings ESP: Boston Scientific has an Earnings ESP of -3.63%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: The company currently carries a Zacks Rank #4 (Sell).

You can see the complete list of today’s Zacks #1 Rank stocks here.

Top MedTech PicksHere are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:

Phibro Animal Health (PAHC - Free Report) has an Earnings ESP of +2.10% and a Zacks Rank #1. The company is expected to release first-quarter fiscal 2027 results soon.

PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.4%. The Zacks Consensus Estimate for the company’s first-quarter EPS indicates an increase of 8.2% from the year-ago quarter’s figure.

IDEXX Laboratories (IDXX - Free Report) has an Earnings ESP of +0.59% and a Zacks Rank #2. The company is slated to release third-quarter 2026 results on Nov. 2.

IDXX’s earnings beat estimates in each of the trailing four quarters, the average surprise being 5.7%. The Zacks Consensus Estimate for the company’s third-quarter EPS implies a jump of 9.1% from the year-ago quarter’s figure.

Becton, Dickinson and Company (BDX - Free Report) , or BD, has an Earnings ESP of +3.28% and a Zacks Rank #2. The company will release its fourth-quarter fiscal 2026 results on Nov. 5.

BD’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.94%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS calls for a rise of 2.5% from the year-ago quarter’s figure.

Louisbourg Investments Inc. grew its holdings in Boston Scientific Corporation (NYSE:BSX – Free Report) by 6.2% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 194,330 shares of the medical equipment provider’s stock after buying an additional 11,377 shares during the quarter. Boston Scientific makes up about 1.5% of Louisbourg Investments Inc.’s investment portfolio, making the stock its 21st largest holding. Louisbourg Investments Inc.’s holdings in Boston Scientific were worth $8,483,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Kelleher Financial Advisors purchased a new stake in Boston Scientific in the second quarter worth $25,000. Clal Insurance Enterprises Holdings Ltd bought a new stake in Boston Scientific in the first quarter valued at $28,000. Nvwm LLC boosted its holdings in Boston Scientific by 526.2% in the third quarter. Nvwm LLC now owns 645 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 542 shares in the last quarter. Rakuten Securities Inc. purchased a new position in Boston Scientific during the 2nd quarter valued at $30,000. Finally, Cassaday & Co Wealth Management LLC purchased a new position in Boston Scientific during the 1st quarter valued at $32,000. 89.07% of the stock is currently owned by institutional investors.

Insider Activity In other Boston Scientific news, CEO Michael F. Mahoney purchased 186,240 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was bought at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the purchase, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David C. Habiger purchased 2,100 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The stock was acquired at an average price of $47.59 per share, with a total value of $99,939.00. Following the completion of the purchase, the director owned 17,160 shares in the company, valued at $816,644.40. This represents a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have acquired 194,522 shares of company stock worth $9,385,210. Corporate insiders own 0.34% of the company’s stock.

Boston Scientific Trading Up 1.2% BSX opened at $45.60 on Wednesday. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a 52 week low of $41.38 and a 52 week high of $105.65. The stock has a market cap of $66.08 billion, a PE ratio of 18.46, a PEG ratio of 1.09 and a beta of 0.58. The business has a 50 day moving average of $45.84 and a 200-day moving average of $49.43. Boston Scientific (NYSE:BSX – Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities research analysts predict that Boston Scientific Corporation will post 3.24 earnings per share for the current fiscal year.

Analyst Ratings Changes Several research analysts have commented on BSX shares. Raymond James Financial restated an “outperform” rating and issued a $57.00 price objective (down from $78.00) on shares of Boston Scientific in a report on Thursday, July 30th. Truist Financial dropped their target price on shares of Boston Scientific from $57.00 to $51.00 and set a “buy” rating for the company in a research report on Wednesday, October 14th. Barclays raised shares of Boston Scientific to a “hold” rating in a research note on Wednesday, October 7th. Robert W. Baird set a $56.00 price target on shares of Boston Scientific in a research report on Thursday, July 30th. Finally, Citigroup reduced their price target on shares of Boston Scientific from $50.00 to $48.00 and set a “neutral” rating on the stock in a research report on Monday, October 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $68.23.

Get Our Latest Report on BSX

(Free Report)

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.

Featured Stories Five stocks we like better than Boston Scientific Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling? Halliburton Gains Traction: Multiyear Upcycle Ahead Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Banque Pictet & Cie SA trimmed its stake in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 65.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 373,583 shares of the medical equipment provider’s stock after selling 694,882 shares during the quarter. Banque Pictet & Cie SA’s holdings in Boston Scientific were worth $16,307,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of BSX. Cyndeo Wealth Partners LLC grew its position in Boston Scientific by 4.3% during the 3rd quarter. Cyndeo Wealth Partners LLC now owns 62,339 shares of the medical equipment provider’s stock worth $2,721,000 after purchasing an additional 2,549 shares during the last quarter. Aspiriant LLC acquired a new position in Boston Scientific in the 3rd quarter valued at about $338,000. Goelzer Investment Management Inc. raised its stake in Boston Scientific by 287.8% during the 3rd quarter. Goelzer Investment Management Inc. now owns 49,215 shares of the medical equipment provider’s stock valued at $2,148,000 after acquiring an additional 36,524 shares during the last quarter. Activest Wealth Management raised its stake in Boston Scientific by 202.6% during the 3rd quarter. Activest Wealth Management now owns 1,831 shares of the medical equipment provider’s stock valued at $87,000 after acquiring an additional 1,226 shares during the last quarter. Finally, V Square Quantitative Management LLC lifted its position in Boston Scientific by 26.4% during the 3rd quarter. V Square Quantitative Management LLC now owns 14,164 shares of the medical equipment provider’s stock worth $618,000 after acquiring an additional 2,956 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analysts Set New Price Targets BSX has been the subject of a number of recent analyst reports. Royal Bank Of Canada reduced their price objective on shares of Boston Scientific from $85.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, July 30th. Citigroup dropped their target price on Boston Scientific from $50.00 to $48.00 and set a “neutral” rating on the stock in a research report on Monday, October 5th. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Wells Fargo & Company reduced their price target on Boston Scientific from $50.00 to $48.00 and set an “equal weight” rating for the company in a report on Wednesday, September 23rd. Finally, Truist Financial decreased their price target on Boston Scientific from $57.00 to $51.00 and set a “buy” rating on the stock in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and an average price target of $68.23.

Read Our Latest Stock Report on BSX Insider Buying and Selling In related news, CEO Michael F. Mahoney bought 186,240 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was bought at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the transaction, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director David C. Habiger bought 2,100 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The stock was purchased at an average price of $47.59 per share, with a total value of $99,939.00. Following the transaction, the director owned 17,160 shares in the company, valued at approximately $816,644.40. This represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought 194,522 shares of company stock valued at $9,385,210 in the last quarter. Company insiders own 0.34% of the company’s stock.

Boston Scientific Stock Up 0.5% Shares of NYSE BSX opened at $44.34 on Friday. Boston Scientific Corporation has a 52-week low of $41.38 and a 52-week high of $105.65. The firm has a fifty day moving average of $46.06 and a 200-day moving average of $49.76. The stock has a market capitalization of $64.26 billion, a PE ratio of 13.75, a P/E/G ratio of 1.07 and a beta of 0.58. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX – Get Free Report) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company’s revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, analysts anticipate that Boston Scientific Corporation will post 3.24 EPS for the current year.

Boston Scientific Company Profile (Free Report)

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.

Read More Five stocks we like better than Boston Scientific Bank of America Stock Sell-Off Looks Like a Buying Opportunity AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff? GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Boston Scientific (BSX - Free Report) ended the recent trading session at $44.14, demonstrating a +2.65% change from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.33%. On the other hand, the Dow registered a gain of 1.08%, and the technology-centric Nasdaq increased by 0.08%.

Shares of the medical device manufacturer witnessed a loss of 2.07% over the previous month, trailing the performance of the Medical sector with its loss of 0.15%, and the S&P 500's gain of 1.41%.

The upcoming earnings release of Boston Scientific will be of great interest to investors. The company's earnings report is expected on October 28, 2026. On that day, Boston Scientific is projected to report earnings of $0.76 per share, which would represent year-over-year growth of 1.33%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.17 billion, up 2.12% from the year-ago period.

For the full year, the Zacks Consensus Estimates are projecting earnings of $3.24 per share and revenue of $21.17 billion, which would represent changes of +5.88% and +5.45%, respectively, from the prior year.

Any recent changes to analyst estimates for Boston Scientific should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 1.49% lower. Currently, Boston Scientific is carrying a Zacks Rank of #4 (Sell).

In the context of valuation, Boston Scientific is at present trading with a Forward P/E ratio of 13.28. This expresses a discount compared to the average Forward P/E of 19.61 of its industry.

One should further note that BSX currently holds a PEG ratio of 1.04. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As of the close of trade yesterday, the Medical - Products industry held an average PEG ratio of 1.82.

The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 96, putting it in the top 40% of all 250+ industries.

The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.

Sysmex (OTCMKTS:SSMXY – Get Free Report) and Boston Scientific (NYSE:BSX – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.

Valuation & Earnings This table compares Sysmex and Boston Scientific”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sysmex $3.32 billion 2.15 $234.01 million $0.42 27.98 Boston Scientific $21.00 billion 2.95 $2.90 billion $2.47 17.29 Boston Scientific has higher revenue and earnings than Sysmex. Boston Scientific is trading at a lower price-to-earnings ratio than Sysmex, indicating that it is currently the more affordable of the two stocks. Volatility and Risk Sysmex has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.

Profitability This table compares Sysmex and Boston Scientific’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets Sysmex 7.62% 8.01% 5.61% Boston Scientific 17.50% 19.28% 10.89% Analyst Ratings This is a breakdown of recent ratings and target prices for Sysmex and Boston Scientific, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sysmex 0 2 0 0 2.00 Boston Scientific 2 6 22 0 2.67 Boston Scientific has a consensus target price of $66.31, suggesting a potential upside of 55.25%. Given Boston Scientific’s stronger consensus rating and higher probable upside, analysts plainly believe Boston Scientific is more favorable than Sysmex.

Insider & Institutional Ownership 89.1% of Boston Scientific shares are held by institutional investors. 0.3% of Boston Scientific shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary Boston Scientific beats Sysmex on 12 of the 14 factors compared between the two stocks.

About Sysmex (Get Free Report)

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, it offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; and lab assay services. Further, the company is involved in the development and sale of software for diagnostic information systems; provision of facility management, office, welfare, and genetic analysis services; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. Additionally, it researches, develops, manufactures, and sells regenerative medicine products; develops, manufactures, and sells biodevices; develops, maintains, and sells computer software; and offers blood DNA testing service. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.

(Get Free Report)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Receive News & Ratings for Sysmex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sysmex and related companies with MarketBeat.com's FREE daily email newsletter.

Boston Scientific (BSX - Free Report) closed the most recent trading day at $42.04, moving +1.11% from the previous trading session. The stock exceeded the S&P 500, which registered a loss of 0.47% for the day. At the same time, the Dow added 0.1%, and the tech-heavy Nasdaq lost 1.25%.

Shares of the medical device manufacturer witnessed a loss of 7.52% over the previous month, trailing the performance of the Medical sector with its loss of 3.97%, and the S&P 500's gain of 1.15%.

Analysts and investors alike will be keeping a close eye on the performance of Boston Scientific in its upcoming earnings disclosure. The company's earnings report is set to go public on October 28, 2026. The company is forecasted to report an EPS of $0.76, showcasing a 1.33% upward movement from the corresponding quarter of the prior year. Simultaneously, our latest consensus estimate expects the revenue to be $5.17 billion, showing a 2.12% escalation compared to the year-ago quarter.

For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.25 per share and a revenue of $21.17 billion, signifying shifts of +6.21% and +5.45%, respectively, from the last year.

Investors might also notice recent changes to analyst estimates for Boston Scientific. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 1.3% decrease. Boston Scientific is holding a Zacks Rank of #4 (Sell) right now.

In terms of valuation, Boston Scientific is currently trading at a Forward P/E ratio of 12.78. This expresses a discount compared to the average Forward P/E of 19.24 of its industry.

We can also see that BSX currently has a PEG ratio of 1. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. BSX's industry had an average PEG ratio of 1.73 as of yesterday's close.

The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 98, placing it within the top 40% of over 250 industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.

Boston Scientific Corporation (NYSE:BSX – Get Free Report) shares hit a new 52-week low on Thursday. The company traded as low as $41.50 and last traded at $41.5470, with a volume of 15871082 shares changing hands. The stock had previously closed at $42.19.

Wall Street Analysts Forecast Growth BSX has been the subject of a number of research analyst reports. Canaccord Genuity Group reduced their target price on Boston Scientific from $70.00 to $66.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Piper Sandler reissued an “overweight” rating and issued a $65.00 price objective on shares of Boston Scientific in a report on Friday, June 12th. Wells Fargo & Company reduced their price objective on Boston Scientific from $50.00 to $48.00 and set an “equal weight” rating for the company in a research note on Wednesday, September 23rd. Leerink Partners set a $60.00 target price on Boston Scientific in a report on Thursday, July 30th. Finally, TD Cowen reiterated a “buy” rating on shares of Boston Scientific in a research report on Thursday, September 17th. Twenty-two research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $66.31.

View Our Latest Stock Analysis on Boston Scientific

Boston Scientific Stock Performance The firm’s fifty day simple moving average is $46.72 and its 200 day simple moving average is $50.90. The company has a market capitalization of $60.21 billion, a PE ratio of 16.82, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. Boston Scientific (NYSE:BSX – Get Free Report) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company’s revenue was up 7.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, research analysts predict that Boston Scientific Corporation will post 3.25 EPS for the current year.

Insider Transactions at Boston Scientific In other news, Director David Habiger acquired 2,100 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were acquired at an average price of $47.59 per share, with a total value of $99,939.00. Following the purchase, the director directly owned 17,160 shares of the company’s stock, valued at $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Edward Ludwig bought 5,000 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The stock was purchased at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the purchase, the director owned 30,359 shares in the company, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought 194,522 shares of company stock valued at $9,385,210 in the last 90 days. 0.34% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Boston Scientific Several institutional investors and hedge funds have recently modified their holdings of BSX. South Plains Financial Inc. purchased a new position in shares of Boston Scientific during the 4th quarter valued at approximately $39,000. Clal Insurance Enterprises Holdings Ltd acquired a new position in Boston Scientific during the first quarter worth $28,000. Cassaday & Co Wealth Management LLC acquired a new position in Boston Scientific during the first quarter worth $32,000. Measured Wealth Private Client Group LLC lifted its holdings in Boston Scientific by 244.9% during the first quarter. Measured Wealth Private Client Group LLC now owns 545 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 387 shares in the last quarter. Finally, Hilton Head Capital Partners LLC acquired a new stake in shares of Boston Scientific in the fourth quarter valued at about $54,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Company Profile (Get Free Report)

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.

Read More Five stocks we like better than Boston Scientific Skydance Just Became a Media Giant—With an $80 Billion Debt Load Could Velo3D Be the Next Defense Buyout Target? Penguin Solutions Is Soaring as AI Memory Demand Explodes Alphabet’s Chart Is Coiling—and the Fundamentals May Be Ready to Back It Up Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

New operating structure designed to increase efficiency and support continued growth MARLBOROUGH, Mass., Oct. 7, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the appointment of Joseph M.

 | Source: Elutia Inc.

Boston Scientific released the full $8 million holdback on schedule and with no claimsEscrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its Avenue Capital loan facility and SimpliDerm® divestitureThe Company is now fully funded through the first year of the expected NXT-41x launch and into 2029 GAITHERSBURG, Md., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced it has received the full $8 million held in escrow in connection with the sale of its BioEnvelope business to Boston Scientific Corporation (NYSE: BSX). The payment was made following an indemnity holdback period that began with the October 1, 2025 closing of the $88 million transaction. The Company believes it is funded through the first full year of the NXT-41x commercial launch and into 2029, without the need for an equity offering.

This is the third of three funding milestones Elutia outlined in its second quarter earnings release, and all three have now been delivered. The Avenue Capital facility closed on August 11, 2026 and the SimpliDerm divestiture closed on August 17, 2026. The regulatory process remains on track and Elutia continues to expect a favorable FDA clearance decision for NXT-41x in the first half of 2027.

"We said we would fund the Company through the NXT-41x launch, and in one quarter we did," said Dr. Randy Mills, CEO of Elutia. "Every milestone we named has landed. Full payment with no claims speaks to the quality of the products Elutia develops and builds. With the balance sheet settled, we are laser-focused on taking this same technology into plastic and reconstructive surgery with NXT-41x, where surgical infection rates can reach 20%."

NXT-41x is the Company’s next-generation antibiotic-eluting surgical matrix. It is being developed for use in the $1.5 billion U.S. plastic and reconstructive surgery market, where complex procedures can carry post-operative infection rates of 15–20%. The product provides soft-tissue reinforcement while delivering antibiotics locally to inhibit bacterial colonization at the surgical site. In an independent blinded survey of 50 board-certified plastic and reconstructive surgeons reported in August 2026, 86% said the matrices they use today increase infection risk, and 96% expressed interest in incorporating NXT-41x into their practice.

About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including any statements and information regarding the size of the U.S. plastic and reconstructive surgery market and the potential of the Company’s next-generation drug-eluting biomatrix pipeline to compete in that market, including the timing and success of NXT-41 and NXT-41x; and the sufficiency of the Company’s capital resources to fund operations through commercialization of NXT-41x and into 2029. These forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to us. Such beliefs and assumptions may or may not prove to be correct. Additionally, such forward-looking statements are subject to a number of known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in the forward-looking statements, including, but not limited to: risks associated with our reliance on a narrower product set, and increasingly on under-development solutions, NXT-41 and NXT-41x; our ability to successfully execute or achieve expected benefits from the divestiture of our SimpliDerm business; the risk that the technology transfer and commercial milestone payments from the SimpliDerm transaction are reduced, delayed, or not earned or received; our ability to enhance our products, expand our product indications and successfully develop, acquire and commercialize additional product offerings, including NXT-41 and NXT-41x; our ability to obtain regulatory approval or other marketing authorizations by the FDA and comparable foreign authorities for our products and product candidates, including NXT-41 and NXT-41x; physician awareness of the distinctive characteristics, benefits, safety, clinical efficacy and cost-effectiveness of our products; our ability to achieve or sustain profitability; our ability to service our indebtedness; our ability to regain compliance with Nasdaq’s minimum bid price requirement and otherwise maintain compliance with any other listing requirement of Nasdaq Capital Market, and our ability to maintain a listing of our Class A common stock on the Nasdaq Capital Market; our ability to raise funds in the future in the amounts and at the times needed; the risk of product liability claims and our ability to obtain or maintain adequate product liability insurance; our ability to defend against the various lawsuits related to FiberCel and VBM, and any other ongoing or future litigation, and avoid a material adverse financial consequence; the continued and future acceptance of our products by the medical community; our dependence on independent sales agents to generate a substantial portion of our net sales; our dependence on a limited number of third-party suppliers and manufacturers, which, in certain cases, are exclusive suppliers for products essential to our business; our ability to successfully realize the anticipated benefits of the sale of our CIED business; our ability to compete against other companies, most of which have longer operating histories, more established products and/or greater resources than we do; pricing pressure as a result of cost-containment efforts of our customers, purchasing groups, third-party payors and governmental organizations could adversely affect our sales and profitability; our ability to obtain, maintain and adequately protect our intellectual property rights; and other important factors which can be found in the “Risk Factors” section of Elutia’s public filings with the Securities and Exchange Commission (“SEC”), including Elutia’s Annual Report on Form 10-K for the year ended December 31, 2025, as such factors may be updated from time to time in Elutia’s other filings with the SEC, accessible on the SEC’s website at www.sec.gov and the Investor Relations page of Elutia’s website at https://investors.elutia.com. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. Any forward-looking statement made by Elutia in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, Elutia expressly disclaims any obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investors
Elutia Investor Relations
[email protected]

Shares of Boston Scientific Corporation (NYSE:BSX – Get Free Report) have been assigned an average rating of “Moderate Buy” from the thirty-one research firms that are covering the company, MarketBeat reports. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and twenty-three have issued a buy rating on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $70.19.

Several analysts have recently issued reports on BSX shares. TD Cowen reaffirmed a “buy” rating on shares of Boston Scientific in a report on Thursday, September 17th. Leerink Partners set a $60.00 target price on shares of Boston Scientific in a report on Thursday, July 30th. Robert W. Baird set a $56.00 price target on shares of Boston Scientific in a research report on Thursday, July 30th. Piper Sandler reiterated an “overweight” rating and set a $65.00 price objective on shares of Boston Scientific in a research report on Friday, June 12th. Finally, Wells Fargo & Company dropped their price objective on shares of Boston Scientific from $50.00 to $48.00 and set an “equal weight” rating for the company in a research note on Wednesday, September 23rd.

Read Our Latest Analysis on BSX

Insider Activity In related news, CEO Michael F. Mahoney acquired 186,240 shares of the firm’s stock in a transaction on Monday, August 3rd. The shares were acquired at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the transaction, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Edward J. Ludwig acquired 5,000 shares of the stock in a transaction dated Friday, July 31st. The stock was bought at an average cost of $45.48 per share, with a total value of $227,400.00. Following the completion of the purchase, the director directly owned 30,359 shares in the company, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have acquired 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is currently owned by corporate insiders. Hedge Funds Weigh In On Boston Scientific Several large investors have recently modified their holdings of the stock. QRG Capital Management Inc. lifted its position in Boston Scientific by 129.4% in the second quarter. QRG Capital Management Inc. now owns 375,620 shares of the medical equipment provider’s stock worth $16,031,000 after buying an additional 211,855 shares during the last quarter. Andra AP fonden increased its position in Boston Scientific by 13.9% during the second quarter. Andra AP fonden now owns 193,622 shares of the medical equipment provider’s stock valued at $8,264,000 after acquiring an additional 23,694 shares during the last quarter. SkyView Investment Advisors LLC bought a new position in Boston Scientific during the second quarter valued at $107,000. Bullseye Investment Management LLC purchased a new stake in shares of Boston Scientific in the second quarter valued at $41,000. Finally, Rench Wealth Management Inc. raised its stake in shares of Boston Scientific by 27.5% in the second quarter. Rench Wealth Management Inc. now owns 27,952 shares of the medical equipment provider’s stock valued at $1,193,000 after acquiring an additional 6,033 shares during the period. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Down 0.8% Shares of BSX stock opened at $43.74 on Wednesday. Boston Scientific has a 12-month low of $42.20 and a 12-month high of $105.65. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The stock’s 50-day moving average price is $46.98 and its 200-day moving average price is $52.06. The stock has a market capitalization of $63.40 billion, a price-to-earnings ratio of 17.71, a price-to-earnings-growth ratio of 1.06 and a beta of 0.57.

Boston Scientific (NYSE:BSX – Get Free Report) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities research analysts predict that Boston Scientific will post 3.26 EPS for the current fiscal year.

Boston Scientific Company Profile (Get Free Report)

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.

Further Reading Five stocks we like better than Boston Scientific CarMax Just Gave Investors a Better Reason to Believe in the Turnaround CoreWeave Comes With Risks: Analysts Split on What Matters Most Bottlenecking the Future: TSMC Prices Out the Competition Fervo Energy Hits Geothermal Milestone: Will It Matter For The Stock?

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Boston Scientific stock slumped 55% over 12 months, driven by weakness in electrophysiology and WATCHMAN, which comprise only 26% of 2025 sales. Despite headline challenges, 74% of BSX's business grew at a robust 7% in Q2 2026, indicating underlying strength. Management cut 2026 guidance three times, with organic growth lowered to 5-6% and EPS guidance trimmed to $3.28-$3.32, amplifying investor pessimism.

Key Takeaways Boston Scientific plans multiple launches through 2028 across Interventional Cardiology, EP and CRM.BSX's FARAWAVE Ultra and ICE entry are expected to help U.S. EP regain momentum in late 2027.BSX expects global EP growth to remain flat in the second half of 2026 as competitive pressures rise. Boston Scientific (BSX - Free Report) is preparing for a steady stream of product launches over the next two years that could become an important source of incremental growth. In Interventional Cardiology, the company plans to launch the SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter in the first half of 2027. Data from the FRACTURE trial, presented as a late-breaker at EuroPCR in May, met all endpoints and showed high rates of freedom from major adverse cardiac events in 30 days, along with procedural success in patients with severely calcified coronary artery disease.

In Endoscopy, Boston Scientific had received FDA clearance for RIVOS, a first-of-its-kind single-device designed to consolidate multiple exchanges and streamline procedural steps while performing endoscopic ultrasound biliary drainage. Physicians have provided positive feedback on initial cases. The company is also advancing enrollment in the THRIVE trial, evaluating the TIVUS Ultrasound System for renal denervation in the treatment of hypertension. Management continues to expect the technology, acquired through the SoniVie Ltd. acquisition, to reach the market in 2028.

Within Cardiac Rhythm Management, Boston Scientific is still facing competitive pressure and portfolio gaps, which it expects to address with PRECEDENT, its new defibrillation platform scheduled to launch in the second half of 2027.

Growth in the company’s Electrophysiology business has been supported by FARAPULSE, which has enabled a faster-than-anticipated transition to pulsed-field ablation (PFA). With U.S. PFA revenues now accounting for approximately 80% of the atrial fibrillation (AFib) market, the company has less room to offset competitive pressures. As a result, it now expects global EP growth to emerge flat in the second half of 2026.

The U.S. EP business is expected to regain momentum in the second half of 2027 with the launch of FARAWAVE Ultra, a high-density mapping and ablation catheter, along with the company’s entry into the intracardiac echocardiography market. Further improvement is forecasted in 2028 with the availability of FARAFLEX, a novel large-focal, high-density mapping and ablation catheter.

BSX Peers UpdateAbbott (ABT - Free Report) recently announced that its Volt PFS system was used for the first time in Canada at the McGill University Health Centre in Montreal to treat AFib patients. The system, designed to integrate with Abbott’s EnSite X EP System to provide physicians with accurate 3D cardiac mapping and fewer catheter exchanges during an ablation, received Health Canada authorization in April 2026. 

Another peer, Globus Medical (GMED - Free Report) , secured CE Mark for Excelsius3D, an intelligent, mobile imaging platform that combines 3D cone-beam computed tomography, 2D fluoroscopy and digital radiography in a single system. Excelsius3D is designed to function as a stand-alone intraoperative imaging platform or as an integrated component of the Excelsius Ecosystem with ExcelsiusGPS. Globus Medical secured FDA’s 510(k) clearance for the system in 2021.

The Zacks Rundown for BSX StockOver the past 12 months, Boston Scientific shares have dropped 55.4% compared with the industry’s 29.7% decline.   

Image Source: Zacks Investment Research

Boston Scientific trades at a forward, five-year Price-to-Sales ratio of 2.85 compared with the 2.11 industry average. 

Image Source: Zacks Investment Research

The company has seen downward revisions in its earnings estimates over the past three months.

Image Source: Zacks Investment Research

BSX stock currently carries a Zacks Rank #5 (Strong Sell).  

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Key Takeaways Boston Scientific expects flat Electrophysiology growth in H2 2026 amid competitive pressure.Medtronic's Cardiac Ablation Solutions revenues rose 88% worldwide and 139% in the United States.Medtronic trades above its 50-day and 200-day SMAs, while Boston Scientific remains below both. The global Electrophysiology device market is valued at $16.73 billion in 2026 and is projected to expand at a 14.31% CAGR from 2026 to 2035, according to Precedence Research. The growing use of these devices in the diagnosis and treatment of cardiovascular diseases, an aging population and advances in high-performance technologies are among the key factors driving market growth. Boston Scientific (BSX - Free Report) and Medtronic plc (MDT - Free Report) are among the major companies competing in this rapidly expanding market.

Boston Scientific develops and manufactures less-invasive medical technologies for diagnosing and treating heart rate and rhythm disorders, including therapeutic and diagnostic catheters and equipment used in electrophysiology labs. Medtronic offers a full suite of electrophysiology solutions for treating arrhythmias, including paroxysmal and persistent atrial fibrillation (AF).

That said, their performance has been notably different over the past three months. BSX has declined 2.1%, while MDT has gained 18.6%. 

Image Source: Zacks Investment Research

Both companies have solid fundamentals, but the key question for investors is which one presents the more attractive investment opportunity at current levels. Let’s analyze.

The Case for Boston ScientificBoston Scientific’s Electrophysiology franchise benefits from the FARAPULSE platform, OPAL mapping system and an expanding catheter pipeline. FARAPULSE has driven the shift to pulsed field ablation (PFA) faster than expected, with U.S. PFA revenues now making up about 80% of the atrial fibrillation (AFib) market. The rapid adoption has also limited the company’s ability to offset competitive pressures, with management expecting Electrophysiology growth to be flat in the second half of 2026.

Third-quarter U.S. Electrophysiology sales are also projected to decline in mid-single digits sequentially. The introduction of FARAWAVE Ultra and entry into intracardiac echocardiography (ICE) could support U.S. performance in the back half of 2027, followed by FARAFLEX launch in 2028.  Internationally, the company expects continued strength, with full-year growth of approximately 20%.

WATCHMAN’s U.S. market has also slowed sharply. New clinical evidence on stroke risk in AF patients has affected patient identification and referral patterns, while rapid adoption of concomitant procedures has created operational inefficiencies between concomitant and standalone workflows. Management expects WATCHMAN sales to decline in mid- to high-single digits in the second half of 2026, with full-year growth to be flat or in low single digits.

Beyond the most pressured Cardiovascular franchises, MedSurg continues to provide a diversified base. Boston Scientific’s acquisition of Nalu Medical expanded its Neuromodulation offerings and delivered a strong full-quarter contribution in the second quarter. Urology remains weak as sacral neuromodulation recovery takes longer than expected and stone-management portfolio gaps persist. Management expects these gaps to be addressed over the next three quarters.

Boston Scientific’s broad geographic footprint remains a long-term growth opportunity. The planned $14.5 billion Penumbra acquisition, expected to close in the second half of 2026, would broaden its presence in the fast-growing areas of the vascular market.

The Case for MedtronicMedtronic is expanding its global Cardiovascular position as several franchises gain share. First-quarter fiscal 2027 Cardiovascular revenues grew 18.9% organically, led by 29.1% growth in Electrophysiology Therapies. Cardiac Ablation Solutions (“CAS”) remains the key growth driver, with revenues up 88% worldwide and 139% in the United States. CAS gained 9 U.S. share points and surpassed $2 billion in trailing 12-month revenues ahead of plan.

The Medical Surgical segment is seeing broader adoption of robotics, digital surgery and core procedural technologies. Medtronic recently formed a strategic partnership with Cornerstone Robotics, building on momentum for its Hugo robotic-assisted surgery system, which received FDA clearance for urologic procedures in December 2025.

In June 2026, Medtronic announced 510(k) submissions to expand Hugo into general and gynecologic procedures in the United States. Management expects Hugo to exceed 50,000 procedures by fiscal 2027 year-end, with procedure growth more than twice the robotic surgery market rate.

Meanwhile, Neuroscience continues to see growth across Cranial & Spinal Technologies, Specialty Therapies and select neuromodulation adjacencies. Medtronic has strengthened its neuromodulation position through the acquisition of SPR Therapeutics and a distribution agreement with Merit Medical. Both segments are growing more than 20% on an annual basis.  The acquisition of Scientia Vascular strengthens the company’s ability to support physicians across the full procedural workflow.

Medtronic is also building its Hypertension business around the Symplicity Spyral renal denervation franchise as reimbursement and adoption improve. Procedure momentum increased following the final Medicare National Coverage Determination. The planned transradial catheter launch in the second half of fiscal 2027 could support broader use by fitting more easily into established interventional workflows.

Still, changing trade policies, inflation and geopolitical disruption remain risks to the company’s operating costs and margin recovery.

A Look at BSX and MDT’s Earnings EstimatesThe consensus estimate for Boston Scientific’s 2026 EPS implies a year-over-year increase of 7.5% to $3.29. The estimate has dropped 1.8% in the past 60 days.

Image Source: Zacks Investment Research

For Medtronic, the fiscal 2027 consensus EPS estimate of $5.97 implies 8% growth from the prior year. The estimate has risen 0.5% over the past 60 days.

Image Source: Zacks Investment Research

BSX & MDT: Technical AnalysisBoston Scientific has been trading below both its 50-day and 200-day simple moving averages (SMAs), indicating weaker near- and longer-term momentum.

Image Source: Zacks Investment Research

In contrast, Medtronic has been trading above both its 50-day and 200-day SMAs, signaling a bullish sentiment. 

Image Source: Zacks Investment Research

EndnoteBoth Medtronic and Boston Scientific stand to benefit from long-term electrophysiology growth. Medtronic’s Cardiovascular growth is led by CAS, while Hugo, SPR Therapeutics and Scientia Vascular add strength across robotic surgery, neuromodulation and procedural care. Meanwhile, Boston Scientific’s key Cardiovascular franchises are under near-term pressure, although MedSurg provides a diversified base. The planned Penumbra acquisition could broaden the company’s vascular presence over time.

Medtronic has an edge in both technical trends and earnings estimate revisions. Its stock has also significantly outperformed BSX over the past three months. Overall, MDT appears worth holding at present, while existing BSX holders may consider exiting until operational visibility improves.

MDT carries a Zacks Rank #3 (Hold), while BSX has a Zacks Rank #5 (Strong Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.

Copyright 2026 Zacks Investment Research 101 N Wacker Drive, Floor 15, Chicago, IL 60606

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.

Visit Performance Disclosure for information about the performance numbers displayed above.

Visit www.zacksdata.com to get our data and content for your mobile app or website.

Real time prices by BATS. Delayed quotes by Sungard.

NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.

This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.

Key Takeaways Boston Scientific's proposed $14.5 billion Penumbra deal expands its thrombectomy presence.Valencia Technologies adds the eCoin system and expands Boston Scientific into ITNS.Closed acquisitions added 340 basis points to BSX's sales in 2025, supporting 15.8% organic growth.
Boston Scientific (BSX - Free Report) has completed numerous acquisitions in recent years as part of its growth strategy, strengthening its core businesses while expanding into high-growth adjacent markets. The latest example is the proposed $14.5 billion purchase of Penumbra, which would expand the company’s presence in thrombectomy, a market focused on removing blood clots and blockages from blood vessels. The transaction is expected to close in the second half of 2026, subject to customary closing conditions, including regulatory clearances, and will be integrated into the Cardiovascular division. The deal is expected to weigh on adjusted earnings per share by 6-8 cents in the first full year after closing, with the earnings impact improving thereafter.

Earlier this year, Boston Scientific also acquired Valencia Technologies, adding the eCoin system to its Urology portfolio. The deal expands the company into implantable tibial nerve stimulation (ITNS), a high-growth adjacency for its Urology business. The deal is expected to have an immaterial impact on adjusted earnings per share in 2026, although it will be more dilutive to GAAP earnings due to acquisition-related net charges and amortization expense.

The company also acquired full ownership of Nalu Medical, Inc., a company developing and commercializing innovative and minimally invasive solutions for patients with chronic pain. Boston Scientific had invested in Nalu since 2017 and previously held an equity stake of approximately 9%. It paid approximately $523 million upfront for the remaining stake, net of cash acquired. The business is being integrated into the Neuromodulation division.

In 2025, closed acquisitions added 340 basis points to sales, contributing to 15.8% organic revenue growth. The addition of Bolt Medical advanced the company’s strategy in coronary and peripheral disease, while the acquisition of SoniVie broadened its Interventional Cardiology Therapies offerings with ultrasound-based renal denervation therapy for hypertension.

BSX Peers UpdateMedtronic (MDT - Free Report)  also focuses on strategic deals that strengthen its leadership across core businesses. The company recently strengthened its Neuroscience portfolio with the acquisition of SPR Therapeutics, Inc., adding short-term, percutaneous peripheral nerve stimulation therapies for chronic and acute pain management. The acquisition is valued at $650 million, consisting of an upfront cash payment. In June, Medtronic completed the buyout of Salt Lake City-based Scientia Vascular for $550 million, with potential undisclosed earn-out and milestone payments post-acquisition.

Stryker (SYK - Free Report) recently signed a definitive agreement to acquire ZuriMED to enhance its shoulder offering. ZuriMED’s FiberLocker System provides a novel approach for rotator cuff augmentation, one of the fastest-growing areas in sports medicine, with increased biomechanical strength to address a key clinical failure mode in rotator cuff repair. In May, Stryker completed the acquisition of Amplitude Vascular Systems to add intravascular lithotripsy (IVL) technology to its peripheral vascular portfolio.

The Zacks Rundown for BSX StockOver the past 12 months, Boston Scientific shares have dropped 56.9% compared with the industry’s 29.8% decline.

Image Source: Zacks Investment Research

Boston Scientific trades at a forward sales multiple of 2.83 over the past 12 months compared with the 2.08 industry average. 

Image Source: Zacks Investment Research

The company’s earnings estimates have been revised downward over the past three months.

Image Source: Zacks Investment Research

BSX stock currently carries a Zacks Rank #4 (Sell).  

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Let's take a look at what these Wall Street heavyweights have to say about Boston Scientific (BSX - Free Report) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.

Boston Scientific currently has an average brokerage recommendation (ABR) of 1.53, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 30 brokerage firms. An ABR of 1.53 approximates between Strong Buy and Buy.

Of the 30 recommendations that derive the current ABR, 21 are Strong Buy and four are Buy. Strong Buy and Buy respectively account for 70% and 13.3% of all recommendations.

Brokerage Recommendation Trends for BSX

Check price target & stock forecast for Boston Scientific here>>>

While the ABR calls for buying Boston Scientific, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.

Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.

In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.

Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.

Zacks Rank Should Not Be Confused With ABRIn spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.

Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.

On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.

Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.

Is BSX Worth Investing In?Looking at the earnings estimate revisions for Boston Scientific, the Zacks Consensus Estimate for the current year has declined 0.3% over the past month to $3.29.

Analysts' growing pessimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates lower, could be a legitimate reason for the stock to plunge in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #5 (Strong Sell) for Boston Scientific. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Therefore, it could be wise to take the Buy-equivalent ABR for Boston Scientific with a grain of salt.

Boston Scientific Corporation (BSX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Concurrent Investment Advisors LLC boosted its holdings in Boston Scientific Corporation (NYSE:BSX – Free Report) by 77.0% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 55,565 shares of the medical equipment provider’s stock after purchasing an additional 24,166 shares during the quarter. Concurrent Investment Advisors LLC’s holdings in Boston Scientific were worth $2,371,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Renaissance Group LLC purchased a new stake in Boston Scientific in the fourth quarter valued at approximately $28,064,000. Perigon Wealth Management LLC acquired a new position in shares of Boston Scientific in the 2nd quarter valued at $883,000. Y Intercept Hong Kong Ltd raised its position in Boston Scientific by 148.8% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider’s stock valued at $47,816,000 after purchasing an additional 670,060 shares during the last quarter. Wealthfront Advisers LLC purchased a new position in Boston Scientific during the 2nd quarter worth $3,253,000. Finally, PensionDanmark Pensionsforsikringsaktieselskab increased its stake in Boston Scientific by 9.9% in the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock valued at $13,659,000 after purchasing an additional 28,961 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Down 5.9% Boston Scientific stock opened at $45.00 on Wednesday. The stock’s 50 day moving average price is $47.04 and its 200 day moving average price is $55.18. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50. The company has a market cap of $65.22 billion, a PE ratio of 18.22, a price-to-earnings-growth ratio of 1.10 and a beta of 0.57. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74.

Boston Scientific (NYSE:BSX – Get Free Report) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business’s revenue was up 7.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, sell-side analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year. Boston Scientific announced that its board has approved a stock repurchase plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its shares are undervalued.

Key Stories Impacting Boston Scientific Here are the key news stories impacting Boston Scientific this week:

Positive Sentiment: Boston Scientific said manufacturing and shipping operations are recovering, which could limit the disruption and support a gradual rebound in revenue and profitability. The company also expects multiple product launches and cost savings to aid longer-term growth. Boston Scientific Says It Won’t Meet 2026 Guidance After Cyberattack Neutral Sentiment: The company has not provided a replacement forecast, leaving investors without clear visibility into the size or duration of the financial impact. Management’s ability to restore systems and normalize shipments will be key near-term catalysts. Boston Scientific says cyberattack likely to hurt 2026 sales, profit Negative Sentiment: Boston Scientific said it is unlikely to meet its 2026 net-sales growth and earnings-per-share guidance ranges, including its previously issued third-quarter and full-year outlook. That reversal is driving the stock’s decline because it signals weaker near-term revenue, profit and cash-flow expectations. Boston Scientific Won’t Meet Guidance Due to Cyberattack Negative Sentiment: The incident adds operational and execution risk to pressure already affecting parts of the portfolio, including WATCHMAN and electrophysiology products. Investors are now likely to focus on the timing of the recovery, the ultimate size of the earnings shortfall and whether customer orders can be fully restored. Boston Scientific’s 2026 Growth Outlook Weakens Insider Activity In other news, Director David C. Habiger bought 2,100 shares of the firm’s stock in a transaction on Wednesday, August 5th. The shares were bought at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the transaction, the director owned 17,160 shares in the company, valued at $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Edward J. Ludwig purchased 5,000 shares of the business’s stock in a transaction dated Friday, July 31st. The shares were purchased at an average cost of $45.48 per share, with a total value of $227,400.00. Following the purchase, the director directly owned 30,359 shares in the company, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders purchased 194,522 shares of company stock worth $9,385,210. Company insiders own 0.34% of the company’s stock.

Analyst Ratings Changes Several equities research analysts have recently weighed in on the stock. Wolfe Research downgraded shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a research note on Friday, May 29th. Weiss Ratings cut Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, July 7th. Robert W. Baird set a $56.00 target price on Boston Scientific in a report on Thursday, July 30th. Citigroup decreased their price target on Boston Scientific from $70.00 to $61.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Finally, Needham & Company LLC dropped their price objective on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a research note on Wednesday, July 8th. Twenty-four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $71.62.

Read Our Latest Stock Report on BSX

Boston Scientific Company Profile (Free Report)

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company’s products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.

Read More Five stocks we like better than Boston Scientific Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Boston Scientific said it likely won't meet its financial guidance due to the cyberattack that has disrupted its operations, sending shares of the medical-technology company down sharply in premarket trading.

The $25k Day Trading Barrier is Gone. It's Time to Put Your Capital to Work.

For years, the PDT rule put a major roadblock in front of active traders. The barrier is no longer standing in the way.

But having more freedom doesn't mean every trade is worth taking. 

With Dynamite Day Trading Signals, you'll receive up to 2 options trade alerts per week, each targeting 50%+ gains in a single session.

NO holding positions overnight.

NO waiting weeks for a trade to develop.

Just focused options trades designed to capitalize on opportunities as they emerge.

👉 Get Access to Dynamite Day Trading Signals

Boston Scientific Corporation (NYSE:BSX) anticipates a material hit to its third-quarter and full-year 2026 financial results following an August cybersecurity incident that disrupted global operations.

The company expects to miss its previously issued net sales and earnings guidance as a result.

Operational Disruptions And Recovery EffortsThe unauthorized activity on certain company systems, detected on Aug. 25, triggered a network outage affecting access to operating systems and business applications.

These system failures hampered the company’s ability to manufacture, process, and ship customer orders.

In response, leadership activated containment protocols and enlisted third-party cybersecurity professionals to investigate the breach.

The company said it has not identified evidence of ongoing unauthorized access to its systems, though the investigation remains ongoing. Boston Scientific has not disclosed whether any data was compromised.

Major distribution centers are now processing and shipping customer orders at or above normal operating levels.

Furthermore, sterilization facilities and most global manufacturing plants are operational again, although a timeline for complete system restoration remains unknown.

Read Next

Financial Outlook And Future UpdatesBecause of the outage, the firm believes it will fall short of the adjusted earnings per share and net sales growth projections issued in late July.

On July 29, the medical device maker guided third-quarter net sales growth of approximately 3%-5% on a reported and organic basis, equivalent to sales of $5.217 billion-$5.318 billion, versus a consensus of $5.358 billion. It had also guided to adjusted earnings of 80-82 cents, against a consensus of 83 cents.

The company now says it is unlikely to reach either range.

While management expects to recoup a portion of the delayed revenue by clearing backlogs and fulfilling pending orders, the complete financial fallout remains unclear.

Executives plan to detail the revised financial and operational outlook during the third-quarter earnings conference call scheduled for Wednesday, Oct. 28.

Despite the near-term headwinds, the company does not foresee the cyberattack causing long-term material damage to its overall financial condition.

BSX Stock Price Activity: Boston Scientific shares were down 5.31% at $45.26 on Tuesday, according to Benzinga Pro data.

Photo: Shutterstock

Read Next

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

BSX's ICVT sales have jumped 15% as coronary therapies gained traction, while new devices and deals could extend its growth momentum.